{"id":27,"date":"2026-05-26T15:54:34","date_gmt":"2026-05-26T15:54:34","guid":{"rendered":"https:\/\/retatrutidebuy.org\/?p=27"},"modified":"2026-05-26T15:54:34","modified_gmt":"2026-05-26T15:54:34","slug":"retatrutide-before-and-after-clinical-data","status":"publish","type":"post","link":"https:\/\/retatrutidebuy.org\/?p=27","title":{"rendered":"Retatrutide Before and After: What Clinical Trial Data Actually Shows"},"content":{"rendered":"<p>The retatrutide before and after story is best told with numbers from the clinical trials, because those are controlled, measured, and verified. Unlike the cherry-picked transformations that dominate social media, trial data includes everyone \u2014 the high responders and the low responders, the people who lost 40% of their body weight and the people who lost 8%. Here is what the full picture looks like.<\/p>\n<h2>Phase 2 Results: 24.2% at 48 Weeks<\/h2>\n<p>The Phase 2 trial published in the New England Journal of Medicine in 2023 enrolled 338 adults with obesity. On the 12 mg dose, participants lost an average of 24.2% of their body weight over 48 weeks. That is roughly 60 pounds for a starting weight of 250 pounds. The trial used a graduated dosing schedule \u2014 2 mg for 4 weeks, 4 mg for 4 weeks, 8 mg for 4 weeks, then 12 mg maintenance \u2014 which became the standard protocol for all subsequent studies.<\/p>\n<h2>TRIUMPH-4: 28.7% at 68 Weeks<\/h2>\n<p>Announced in December 2025, TRIUMPH-4 studied retatrutide in adults with obesity and knee osteoarthritis. The results: 28.7% average weight loss \u2014 71.2 pounds \u2014 at 68 weeks. Participants also reported significant improvement in knee pain, suggesting that the weight loss translated into measurable functional benefits. This was the first Phase 3 trial to report results, and the 28.7% number exceeded most analyst expectations.<\/p>\n<h2>TRIUMPH-1: 30.3% in the Highest-Risk Group<\/h2>\n<p>The May 2026 TRIUMPH-1 results represent the strongest retatrutide data to date. On the 12 mg dose: 28.3% weight loss at 80 weeks. In the subgroup with a BMI of 35 or higher who remained on the drug for the full duration: 30.3% weight loss \u2014 85 pounds \u2014 at 104 weeks. The Pharmaceutical Journal reported that &#8220;all doses resulted in clinically meaningful weight loss,&#8221; with the 4 mg dose producing approximately 15-17% and the 8 mg dose producing 22-24%.<\/p>\n<h2>The Maintenance Question<\/h2>\n<p>The TRIUMPH-1 data shows that weight loss is sustained for at least two years with continued dosing, with no evidence of metabolic adaptation causing significant regain during that period. TRIUMPH-5, which is specifically designed to measure what happens when patients stop retatrutide after initial weight loss, has not yet reported results. Based on experience with tirzepatide and semaglutide, significant regain is expected when the drug is discontinued \u2014 the SURE trial showed that semaglutide users regained two-thirds of their lost weight within one year of stopping.<\/p>\n<h2>What the Data Does Not Show<\/h2>\n<p>The clinical trials do not include photos, testimonials, or individual success stories. They report averages, standard deviations, and statistical significance. The before and after that matters for an individual is not the average \u2014 it is their own response. Some people lose 40% on retatrutide. Some lose 10%. The trial data tells you what is possible and what is probable. It does not tell you what will happen to you.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The retatrutide before and after story is best told with numbers from the clinical trials, because those are controlled, measured, and verified. Unlike the cherry-picked transformations that dominate social media, trial data includes everyone \u2014 the high responders and the low responders, the people who lost 40% of their body weight and the people who [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-27","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/27","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=27"}],"version-history":[{"count":0,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=\/wp\/v2\/posts\/27\/revisions"}],"wp:attachment":[{"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=27"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=27"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/retatrutidebuy.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=27"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}